Table of Contents page: European Journal of Cancer

Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis

Hanfang Jiang,
Quchang Ouyang,
Yongmei Yin,
...
Luping Meng,
Youzhi Tong,
Huiping Li

Published online: September 28, 2022

p1-12

Open Access

Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy

Sora Kang,
So H. Lee,
Hee J. Lee,
...
Saebyeol Lee,
Jongwon Lee,
Sung-Bae Kim

Published online: September 29, 2022

p30-40

Open Access

Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study

Gilles Houvenaeghel,
Alexandre de Nonneville,
Monique Cohen,
...
Patrice Crochet,
Sandrine Rua,
Anthony Gonçalves

Published online: October 01, 2022

p58-69

Open Access

Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers

Alexandre de Nonneville,
Gilles Houvenaeghel,
Monique Cohen,
...
Frederic Viret,
Anthony Gonçalves,
François Bertucci

Published online: October 15, 2022

p181-188

Open Access

Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma

Markus Moehler,
Anica Högner,
Anna D. Wagner,
...
Peter Thuss-Patience,
Hanneke van Laarhoven,
Elizabeth Smyth

Published online: September 29, 2022

p13-29

$Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer$

Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer

Dae Won Kim,
Young-chul Kim,
Bence P. Kovari,
...
Daneng Li,
Wungki Park,
Richard D. Kim

Published online: October 14, 2022

p171-180

Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation

Marcus Unterrainer,
Christophe M. Deroose,
Ken Herrmann,
...
on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group,
the European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Group,
the European Society of Oncologic Imaging (ESOI) and the European Society of Gastrointestinal and Abdominal Radiology (ESGAR)

Published online: October 20, 2022

p193-206

Open Access

Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients

Yasuhiro Nakamura,
Kenjiro Namikawa,
Yukiko Kiniwa,
...
Motoo Nomura,
Yoshiyasu Umeda,
Naoya Yamazaki

Published online: October 01, 2022

p78-87

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study

Patricio Serra-Bellver,
Judith M. Versluis,
Honey K. Oberoi,
...
James M.G. Larkin,
Christian U. Blank,
Paul Lorigan

Published online: October 07, 2022

p121-132

Open Access

Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS)

Stefan S. Bielack,
Claudia Blattmann,
Arndt Borkhardt,
...
Irene von Luettichau,
Reinhard Windhager,
Stefanie Hecker-Nolting

Published online: September 30, 2022

p50-57

A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery

Evan Rosenbaum,
Rashmi Chugh,
Christopher W. Ryan,
...
Gary K. Schwartz,
Robert G. Maki,
Richard D. Carvajal

Published online: October 08, 2022

p155-163

Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis

Frederik O. Meeuwes,
Mirian Brink,
Marjolein W.M. van der Poel,
...
Gerwin A. Huls,
Joost S.P. Vermaat,
Marcel Nijland

Published online: October 05, 2022

p100-109

Open Access

The clinical utility of dysregulated microRNA expression in paediatric solid tumours

Karan R. Chadda,
Ellen E. Blakey,
Nicholas Coleman,
Matthew J. Murray

Published online: October 07, 2022

p133-154

Open Access

Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life

Thomas U. Schulz,
Sarah Zierold,
Michael M. Sachse,
...
Katharina C. Kähler,
Lars E. French,
Lucie Heinzerling

Published online: October 02, 2022

p88-99

DeepClassPathway: Molecular pathway aware classification using explainable deep learning

Elia Lombardo,
Julia Hess,
Christopher Kurz,
...
Claus Belka,
Guillaume Landry,
Kristian Unger

Published online: September 30, 2022

p41-49

Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy

Joanne S. Evans,
Jamie Beaumont,
Marta Braga,
...
Stephen Archibald,
Eric O. Aboagye,
Rohini Sharma

Published online: October 05, 2022

p110-120

Open Access

Access and quality of biomarker testing for precision oncology in Europe

Nicola Normanno,
Kathi Apostolidis,
Audrey Wolf,
...
Etienne Rouleau,
Simon Patton,
Victoria Williams

Published online: October 01, 2022

p70-77

Open Access

Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?

Vincenzo Di Noia,
Fulvia Pimpinelli,
Davide Renna,
...
Raul Pellini,
Aldo Morrone,
Francesco Cognetti

Published online: October 09, 2022

p164-167

FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: Is there hope?

Clara Helal,
Marine Valéry,
Michel Ducreux,
Antoine Hollebecque,
Cristina Smolenschi

Published online: October 13, 2022

p168-170

Regression of intestinal diffuse large B cell lymphoma after treatment with vedolizumab in a patient with Crohn's disease

Shuji Yamamoto,
Takero Shindo,
Hiroki Kitamoto,
Takeshi Kuwada,
Hiroshi Seno

Published online: October 15, 2022

p189-192

Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study

Muhammad A. Khattak,
Jason J. Luke,
Georgina V. Long,
...
Clemens Krepler,
Alexander M.M. Eggermont,
John M. Kirkwood

Published online: October 03, 2022

p207-217

November 2022

Breast cancer

Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis

Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy

Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study

Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers

Gastrointestinal oncology

Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma

Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer

Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation

Melanoma and skin cancers

Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study

Sarcoma

Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS)

A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery

Hematology

Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis

Pediatric oncology

The clinical utility of dysregulated microRNA expression in paediatric solid tumours

Quality of life

Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life

Basic science and preclinical research

DeepClassPathway: Molecular pathway aware classification using explainable deep learning

Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy

Other

Access and quality of biomarker testing for precision oncology in Europe

Correspondence

Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?

FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: Is there hope?

Regression of intestinal diffuse large B cell lymphoma after treatment with vedolizumab in a patient with Crohn's disease

Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study